<div id="readability-page-1"><div><p><span>WuXi Biologics (Cayman) </span><span>:</span></p><ul><li>FY REVENUE RMB 21,790 MILLION</li><li>FY PROFIT EXPECTED TO INCREASE TO RMB5,733 MILLION</li><li>FY ADJUSTED  NON-IFRS NET PROFIT EXPECTED TO INCREASE TO RMB6,586 MILLION</li></ul></div></div>

<p>WuXi Biologics (Cayman) :FY REVENUE RMB 21,790 MILLIONFY PROFIT EXPECTED TO INCREASE TO RMB5,733 MILLIONFY ADJUSTED NON-IFRS NET PROFIT EXPECTED TO INCREASE TO RMB6,586 MILLION</p>

Reuters

Yinhua CSI Innovative Drugs Industry ETF

Invesco Biotechnology & Genome ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ICBCCS SSE STAR Biology and Medicine ETF

ALPS Medical Breakthrough

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

China Merchants CSI Biotechnology Theme ETF

VG Health

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Penghua CSI HK Connect Health Care Composite ETF

WuXi Biologics

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

VanEck Biotech ETF

Health Care Select Sector SPDR

WUXI BIO

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

iShares US Pharma

E Fund CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

iShares Global Healthcare

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Proshares Ultra Nasdaq Biotech

Wuxi Biologics FY Revenue RMB21,790 Million